Insilico Medicine Is Said to Aim for HK IPO in Coming Weeks

Insilico Medicine Inc. aims to list in Hong Kong as soon as this month, according to people familiar with the matter, rounding out a more than four-year effort to go public.

The company, a drug discovery and development platform supported by generative artificial intelligence, intends to raise about $300 million, the people said, asking not to be identified because the information is private.

The China Securities Regulatory Commission released a statement Tuesday evening saying it approved Insilico issuing as many as 108.9 million shares.

Insilico had earlier declined to comment on the timing and size of an offering.

Read More: ...